La NMPA de China aprueba la comercialización de Ganagliflozin Proline Tablets

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#NMPA #ChinaDrugApproval #GanagliflozinProline #SGLT2Inhibitor #Type2Diabetes #InnovativeDrug #PharmaceuticalNews

China NMPA Approves Pradefovir Mesylate Tablets for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPA #ChinaDrugApproval #PradefovirMesylate #Xinshumu #HepatitisB #InnovativeDrug #XiAnGelanXintong #PharmaceuticalNews

FDA Announces Nationwide Recall of ADHD Medication—Check Your Cabinets Now Sun Pharmaceutical Industries has recalled several lots lisdexamfetamine dimesylate capsules, a generic form of Vyvanse, after testing found they failed to dissolve properly.

ADHD medication recalled due to failed specs. More info 👉: www.health.com/adhd-medicat...

#MedicationSafety #PharmaceuticalNews #HealthNews #HealthUpdates #PatientSafety #ADHDsky

China NMPA Approves Icodec Insulin Injection(Awiqli) for Market Launch

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#InsulinIcodec
#Awiqli
#NovoNordisk
#NMPAApproval
#ChinaDrugAdministration
#Type2Diabetes
#LongActingInsulin
#DiabetesTreatment
#PharmaceuticalNews
#2024DrugApprovals

Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial - Investopedia Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial  Investopedia

Click Subscribe #SareptaTherapeutics #ClinicalTrials #StockMarket #Investopedia #PharmaceuticalNews

Novartis Cosentyx fails in late-stage giant cell arteritis trial Investing.com -- Novartis (SIX:NOVN) announced Thursday that its Cosentyx drug did not meet its primary goal in a Phase III trial for adults with giant cell arteritis (GCA). The drug failed to demonstrate an improvement in sustained remission among patients with newly diagnosed or relapsing GCA, according to the Swiss pharmaceutical company. Shreeram Aradhye, president of development and chief medical officer at Novartis, said: "While the Phase III results did not replicate the positive outcomes observed in the Phase II trial, we remain committed to continuing to drive scientific progress and deepening the understanding of immune-mediated diseases." This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Novartis #Cosentyx #GiantCellArteritis #ClinicalTrials #PharmaceuticalNews

Pharma Industry Insights: Trump Administration Aims to Reduce Prescription Drug Costs by 80% Today, President Donald Trump signed an executive order reinstating the "most favored nation" (MFN) policy, aiming to align U.S. prescription drug prices with

Big Pharma Shake-Up
President Trump just signed an executive order to slash U.S. prescription drug prices by as much as 80%!
#DrugPricing #HealthcareReform #PharmaceuticalNews #TrumpPolicy #Medicare

prismmarketview.com/pharma-indus...

Eli Lilly Faces Setback as CVS Drops Zepbound Coverage - WIOBS Eli Lilly’s obesity drug Zepbound loses CVS coverage, raising concerns over sales momentum as competition with Novo Nordisk’s...

Eli Lilly Faces Setback as CVS Drops Zepbound Coverage
wiobs.com/eli-lilly-fa...
#EliLilly #Zepbound #CVSHealth #ObesityDrug #Wegovy #PharmaceuticalNews #HealthCare #WeightLossDrugs #DrugCoverage #PharmaMarket

چیف ڈرگ کنٹرولر پنجاب نے مراسلہ جاری کردیا
مزید پڑھیے: www.aaj.tv/news/30445407
#AajNews #Punjab #MedicineBan #HealthSafety #DrugControl #PharmaceuticalNews

FDA and MFDS Approve ImmunoForge’s Leading Drugs for DMD and CML, Accelerating Clinical Trials ImmunoForge, a pioneering biotech company, is making significant strides in the treatment of serious medical conditions with the recent approval of two Investigational New Drug (IND) applications by r...

www.linkedin.com/pulse/fda-mf...

FDA and MFDS Approve ImmunoForge’s Leading Drugs for DMD and CML, Accelerating Clinical Trials

kstrategyand.com/pharma-news

#ImmunoForge #FDAApproval #Pemziviptadil #DMDCardiomyopathy #PharmaceuticalNews #FDA #MFDS #Humanteconomy #Humantec #KStrategyand